Certara Launches D360 in Japan to Improve Drug Discovery and Development Productivity
D360™ provides enhanced data access and visualization to enable rapid decision making and reduce attrition rates
TOKYO & ST. LOUIS--(BUSINESS WIRE)--Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced the launch in Japan of D360, its integrated solution for the query, analysis and visualization of drug discovery and development data.
“D360 is a well-established, trusted drug discovery and development data access and analysis solution that can help pharma and biotech companies to improve the time to and accuracy of their go/no-go product decisions by providing scientists with on-demand access to their desired data in their preferred format.”
D360 is used by scientists in both discovery and pre-clinical research. It allows them to search, analyze and share their data without the need for constant IT support, helping to shorten the drug discovery cycle.
In preclinical drug discovery, searching historical control data to answer questions from regulatory agencies often requires the manual review of multiple study reports, which can entail days or weeks of effort. With D360, scientists can obtain the necessary cross-study data views in minutes, allowing them to provide an immediate response to regulatory bodies, and avoiding costly delays in approval processes and disruptions to ongoing work.
In early phase discovery research, scientists use D360 to get a comprehensive view of all project-relevant data, in which data summarization is performed, according to corporate standard scientific business rules, at the click of a button. Decision making at project meetings becomes more efficient since the effort required for data collation is practically eliminated. Consistent data presentation minimizes discussion about data collation methods, and the ability to drill down on aggregated data and use follow-on queries allows supporting information to be obtained in situ.
“We are proud to introduce D360 to the Japanese market,” said Certara CEO Edmundo Muniz, M.D., Ph.D. “D360 is a well-established, trusted drug discovery and development data access and analysis solution that can help pharma and biotech companies to improve the time to and accuracy of their go/no-go product decisions by providing scientists with on-demand access to their desired data in their preferred format.”
D360 is already deployed in life sciences research organizations of all sizes including six top 15 pharma companies. D360 is being used by a variety of disciplines at organizations such as Pfizer, Boehringer Ingelheim, Medivir AB, Plexxikon, and Agios to provide: one-click access to project data views for discovery scientists; ad-hoc query capabilities for molecular design and hypothesis testing; real-time preclinical study monitoring; and cross-study analysis of pre-clinical data.
Certara currently has more than 200 clients in Japan, including all the top 20 Japanese pharmaceutical companies. D360 will be deployed and supported by the Certara KK office in Tokyo, which was established in 2011.
Certara is the leading global technology-enabled drug development and drug safety consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.